Latest News - Bausch+Lomb

Wednesday, June 21, 2017 | Product Releases, Retina, Bausch+Lomb

Bausch + Lomb Unveils AMD Virtual Experience with State-of-the-Art Technology at Optometry’s Meeting

Bausch + Lomb announced the launch of a new virtual reality tool using state-of-the-art technology. The Age-Related Macular Degeneration (AMD) Virtual Experience, unveiled during the annual meeting of…

Read the full story

Tuesday, June 06, 2017 | Acquisitions/Mergers, Bausch+Lomb, Carl Zeiss Meditec, Valeant

Report: Valeant in Talks to Sell Bausch + Lomb's Surgical Business to Carl Zeiss

Valeant is in in talks to sell its Bausch & Lomb unit’s surgical products business to Carl Zeiss Meditec, according to a Bloomberg report, which cited people familiar with the matter. Valean…

Read the full story

Monday, May 22, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Renu Advanced Formula Multi-Purpose Solution

Bausch + Lomb announced the launch of "renu Advanced Formula" multi-purpose solution for soft and silicone hydrogel contact lenses. The formula combines three disinfectants and two surfactan…

Read the full story

Wednesday, May 10, 2017 | Medical Studies, Bausch+Lomb

Bausch + Lomb Reports Updated Results of the ARMOR Study

Bausch + Lomb announced updated results from the ARMOR (Antibiotic Resistance Monitoring in Ocular MicRoorganisms) surveillance study, the only multicenter, nationwide survey of antibiotic resistance …

Read the full story

Tuesday, May 09, 2017 | Clinical Trials, Bausch+Lomb, Valeant

Bausch + Lomb Announces PDUFA Date For Luminesse

Bausch + Lomb announced that the FDA accepted the new drug application (NDA) for brimonidine tartrate ophthalmic solution, 0.025% (Luminesse), and set a PDUFA action date of December 27, 2017. Lumines…

Read the full story

Wednesday, May 03, 2017 | Conferences, ASCRS, Bausch+Lomb

Bausch + Lomb Invites Surgeons to Test Drive New Next-Generation Phacoemulsification Platform at the ASCRS Meeting in Los Angeles

Bausch + Lomb announced that surgeons can sign up to test drive the new Stellaris Elite vision enhancement system, the company’s next generation phacoemulsification platform, at a wet lab in its…

Read the full story

Tuesday, May 02, 2017 | Conferences, Bausch+Lomb

Bausch + Lomb Letter to Eye Care Professionals: Taking Phaco into the Future

Chuck Hess, Vice President & General Manager, U.S. Surgical, Bausch + Lomb, wrote the following letter to eye care professionals detailing new products and plans for the upcoming ASCRS meeting in …

Read the full story

Wednesday, April 26, 2017 | FDA Approval/Clearance, Bausch+Lomb

Bausch + Lomb Receives 510(k) Clearance from FDA for Vitesse Vitrectomy System

Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Vitesse, the first and only hypersonic, 100% open port vitrectomy system, according to a company news release. This new t…

Read the full story

Thursday, April 06, 2017 | FDA Approval/Clearance, Product Releases, Bausch+Lomb

Bausch + Lomb Receives FDA 510(k) Clearance for Stellaris Elite Phacoemulsification Platform

Bausch + Lomb announced that it has received 510(k) clearance from the FDA for the Stellaris Elite vision enhancement system, the company’s next generation phacoemulsification platform. The mach…

Read the full story

Thursday, March 30, 2017 | Management/Leadership, Bausch+Lomb, Valeant

Bausch + Lomb Announces US Management Team Leadership

Bausch + Lomb announced several changes to its management team designed to improve operational efficiencies. Joseph “Joe” Gordon, senior vice president and general manager, US Consumer …

Read the full story

Thursday, March 30, 2017 | Product Releases, Bausch+Lomb

Introducing Bausch + Lomb ULTRA for Astigmatism Contact Lenses

Bausch + Lomb announced the launch of Bausch + Lomb ULTRA for Astigmatism contact lenses, an innovative monthly silicone hydrogel lens that combines MoistureSeal technology, which helps to maintain 95…

Read the full story

Tuesday, March 21, 2017 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb and Nicox Announce PDUFA Date For Novel Glaucoma Candidate Latanoprostene Bunod

Bausch + Lomb and Nicox announced that the FDA has set a deadline of August 24, 2017 for its decision on the new drug application for latanoprostene bunod ophthalmic solution, 0.024%. Latanoprostene b…

Read the full story

Tuesday, March 07, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb UK/I Launches Digital Hub

Bausch + Lomb announced the launch of their enhanced digital hub Bausch.co.uk, a destination for patients and health care professionals to access the latest information on eye concerns and associated …

Read the full story

Thursday, March 02, 2017 | Conferences, Bausch+Lomb

Bausch + Lomb Educates Over 200 Eye Care Professionals During B+Lieve Symposium in San Francisco

Bausch + Lomb continued its educational and training initiative for eye care professionals with the year’s first B+Lieve symposium in San Francisco from February 27-28, 2017. During the event, m…

Read the full story

Wednesday, March 01, 2017 | Product Releases, Bausch+Lomb

Bausch + Lomb Introduces Biotrue ONEday for Astigmatism Contact Lenses

Bausch + Lomb announced the introduction of Biotrue ONEday for Astigmatism daily disposable contact lenses. Approximately 73.2 million people in the U.S. are astigmatic, but only 8.8 million people ar…

Read the full story
Load More